Holen Sie sich die Stockscreener-App
21.82
0.46%
-0.10
Handel nachbörslich:
21.86
0.04
+0.18%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TEVA?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$21.92
Offen:
$22.06
24-Stunden-Volumen:
6.25M
Relative Volume:
0.76
Marktkapitalisierung:
$24.72B
Einnahmen:
$16.77B
Nettoeinkommen (Verlust:
$-959.00M
KGV:
-25.67
EPS:
-0.85
Netto-Cashflow:
$1.37B
1W Leistung:
+4.00%
1M Leistung:
-1.22%
6M Leistung:
+29.80%
1J Leistung:
+95.17%
1-Tages-Spanne:
$21.65
$22.08
1-Wochen-Bereich:
$21.21
$22.10
52-Wochen-Spanne:
$11.08
$22.80
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Company Profile
Firmenname
Teva Pharmaceutical Industries Ltd Adr
Sektor
Telefon
972 (3) 914-8213
Adresse
TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV
Vergleichen Sie TEVA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.82 | 24.72B | 16.77B | -959.00M | 1.37B | -0.85 |
|
ZTS
Zoetis Inc
|
167.53 | 75.58B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.24 | 41.78B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.10 | 41.53B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
NBIX
Neurocrine Biosciences Inc
|
145.88 | 14.77B | 2.24B | 385.90M | 440.10M | 3.73 |
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-10 | Hochstufung | Argus | Hold → Buy |
| 2024-03-08 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-02-12 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-01-23 | Hochstufung | Jefferies | Hold → Buy |
| 2024-01-03 | Hochstufung | Piper Sandler | Underweight → Neutral |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-11-27 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-06 | Hochstufung | UBS | Sell → Neutral |
| 2023-05-25 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-05-18 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-01-19 | Herabstufung | Jefferies | Buy → Hold |
| 2022-11-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-11-04 | Herabstufung | UBS | Neutral → Sell |
| 2022-10-21 | Fortgesetzt | Jefferies | Buy |
| 2022-08-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-06-14 | Fortgesetzt | UBS | Neutral |
| 2022-05-17 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-05-04 | Herabstufung | Piper Sandler | Neutral → Underweight |
| 2022-04-05 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-03-25 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2022-01-27 | Herabstufung | Argus | Buy → Hold |
| 2021-10-28 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-05-04 | Herabstufung | UBS | Buy → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2020-11-25 | Eingeleitet | Oppenheimer | Perform |
| 2020-08-06 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2020-07-27 | Fortgesetzt | Goldman | Neutral |
| 2020-06-01 | Hochstufung | SunTrust | Hold → Buy |
| 2020-04-24 | Fortgesetzt | Citigroup | Neutral |
| 2020-04-06 | Hochstufung | UBS | Neutral → Buy |
| 2020-02-24 | Herabstufung | Edward Jones | Hold → Sell |
| 2019-11-12 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-10-17 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2019-08-07 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-07-19 | Eingeleitet | Wolfe Research | Peer Perform |
| 2019-07-15 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2019-07-10 | Fortgesetzt | Credit Suisse | Neutral |
| 2019-07-05 | Hochstufung | Argus | Hold → Buy |
| 2019-06-11 | Eingeleitet | Barclays | Underweight |
| 2019-06-03 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-05-30 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2019-05-28 | Herabstufung | UBS | Buy → Neutral |
| 2019-03-20 | Eingeleitet | SunTrust | Hold |
| 2019-03-07 | Fortgesetzt | UBS | Buy |
Alle ansehen
Teva Pharmaceutical Industries Ltd Adr Aktie (TEVA) Neueste Nachrichten
Pain Management Therapeutics Market Is Expected To Reach Revenue Of USD 120.7 Bn By 2033, At 3.9% CAGR: Dimension Market Research. - GlobeNewswire Inc.
Citigroup Inc (NYSE: C) Up 37.25% This Year: What Is Going To Happen Next - Stocks Register
Where Do Analysts Think The Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) Is Going - Stocks Register
Fortuna Mining Corp Still Hasn’t Convinced Analysts? - Stocks Register
Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) 0.56% Incline Turns Investors Away - Stocks Register
Is Now The Time To Buy Abbvie Inc (NYSE: ABBV) Stock? - Stocks Register
PayPal Holdings Inc (NASDAQ: PYPL) Could Pass $95 In One Year Stock Forecast - Stocks Register
How Do Things Look For Boeing Co (NYSE: BA) In The Short-Term? - Stocks Register
What Did We Note About Insider Trading At Energy Transfer LP (NYSE: ET)? - Stocks Register
SelectQuote Inc Still Hasn’t Convinced Analysts? - Stocks Register
Barclays plc ADR (NYSE: BCS) Stock Sentiment: What’s Wall Street Saying? - Stocks Register
What Did We Note About Insider Trading At Altice USA Inc (NYSE: ATUS)? - Stocks Register
Walmart Inc (NYSE: WMT) -2.05% Decline Turns Investors Away - Stocks Register
What Did We Note About Insider Trading At Microsoft Corporation (NASDAQ: MSFT)? - Stocks Register
Where Do Analysts Think The Itau Unibanco Holding S.A. ADR (NYSE: ITUB) Is Going - Stocks Register
Hewlett Packard Enterprise Co (NYSE: HPE) Up 28.35% This Year: What Is Going To Happen Next - Stocks Register
Teva Pharmaceutical ADR Clears Technical Benchmark, Hitting 90-Plus RS Rating - Investor's Business Daily
Sandoz Group AG Sponsored ADR (SDZNY) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
Wall Street Analysts Think Molecular Partners AG Sponsored ADR (MOLN) Could Surge 80.72%: Read This Before Placing a Bet - Yahoo Finance
Is Kingsoft Cloud (KC) Outperforming Other Computer and Technology Stocks This Year? - Yahoo Finance
Opera Gains 27% in 3 Months: Should You Buy, Sell or Hold the Stock? - Yahoo Finance
Upcoming Nasdaq-100 changes could boost the stocks of these 11 companies - Yahoo Finance
Teva Pharmaceutical ADR Clears Technical Benchmark, Hitting 80-Plus RS Rating - Investor's Business Daily
Hello Group Inc. Sponsored ADR (MOMO) Surpasses Q3 Earnings and Revenue Estimates - Yahoo Finance
Foot Locker Inc (FL) Strikes $22.38: The Risk Seems Worthwhile At This Price - Stocks Register
Teva Pharmaceutical ADR Gets Relative Strength Rating Upgrade - Investor's Business Daily
Saudi Arabia Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
Why Sony Group Corporation (SONY) Is One of the Best ADR Stocks to Invest in? - Yahoo Finance
Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year? - Yahoo Finance
New Strong Buy Stocks for November 26th - Yahoo Finance
Why MINISO Group Holding Limited Unsponsored ADR (MNSO) Outpaced the Stock Market Today - Yahoo Finance
Petrobras to Distribute R$ 20 Billion in Dividends - Yahoo Finance
10 Stocks With the Largest Fair Value Estimate Increases After Q3 Earnings - Morningstar
Is Atour Lifestyle Holdings Limited Sponsored ADR (ATAT) Outperforming Other Consumer Discretionary Stocks This Year? - Yahoo Finance
Full Truck Alliance Co. Ltd. Sponsored ADR (YMM) Q3 Earnings and Revenues Beat Estimates - Yahoo Finance
UK Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
XPeng Inc. Sponsored ADR (XPEV) Increases Despite Market Slip: Here's What You Need to Know - Yahoo Finance
Sea Limited Q3 Earnings Miss Estimates, Shares Rise on Revenue Growth - Yahoo Finance
Such Is The Power Of CNH Industrial NV (NYSE: CNH) - Stocks Register
Hannover Rueck SE Reports Strong 2024 Earnings Growth - Yahoo Finance
Weekly Upgrades and Downgrades - InvestorPlace
Teva Pharmaceutical Industries ADR (TEVA-N) QuotePress Release - The Globe and Mail
XPeng Inc. Sponsored ADR (XPEV) Stock Moves -1.06%: What You Should Know - Yahoo Finance
Where Do Analysts See Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) Heading? - Stocks Register
Biliary Tract Cancer Market Research Report 2024-2030 with Analyst Recommendations - GlobeNewswire Inc.
Sea Limited Sponsored ADR (SE) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
Li Auto Inc. Sponsored ADR (LI) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
South Africa Central Nervous System Therapeutic Market Size & Outlook, 2028 - Grand View Research
Is Alstom (ALSMY) Outperforming Other Transportation Stocks This Year? - Yahoo Finance
Spain Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
Italy Central Nervous System Therapeutic Market Size & Outlook, 2028 - Grand View Research
Finanzdaten der Teva Pharmaceutical Industries Ltd Adr-Aktie (TEVA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):